Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancerGlobeNewsWire • 09/16/24
Security Services Market Report 2024 & Competitive Analysis for ADT, Allied Universal, Brink's, Prosegur and SecuritasGlobeNewsWire • 08/26/24
Strength Seen in ADT (ADT): Can Its 7.9% Jump Turn into More Strength?Zacks Investment Research • 06/24/24
ADT Appoints Dan Houston and Danielle Tiedt to the Company's Board of DirectorsGlobeNewsWire • 06/17/24
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ADT Inc. (NYSE: ADT)PRNewsWire • 04/01/24